Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling ...

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334 (5):296-301. doi: 10.1056/NEJM199602013340504 ...

Virtual echocardiography screening tool scores calculated via algorithm matched manually calculated scores and are promising ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...

Chest. 2012;142:448—456. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889.

Five patients (4-9 yrs.) presented in five years with primary pulmonary hypertension (PPH). Each was initially evaluated for seizures or syncope. Two sisters (#1s2) were Hispanic and resided at ...

WAYNE, N.J., Oct. 22, 2012 -- /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III PATENT-1 pulmonary arterial hypertension (PAH) trial evaluating its investigational drug ...

Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

Pulmonary hypertension is elevated blood pressure that occurs exclusively in the lungs. It is a deadly condition that affects an estimated 75 million people worldwide. Around 80% of them live in ...

- Conference call and webcast with guest pulmonary key opinion leaders to be held today, Monday, January 27th at 5:00 p.m. EST - January 27, 2020 04:01 PM Eastern Standard Time ...